Richard S. Finn
理查德·芬恩
MD
Professor of Medicine, Division of Hematology/Oncology血液肿瘤内科学教授
👥Biography 个人简介
Richard Finn is a global authority on HCC systemic therapy. He led the IMbrave150 trial establishing atezolizumab plus bevacizumab as standard first-line therapy for advanced HCC, and was central to the SHARP sorafenib trial. His work has redefined HCC treatment paradigms worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IMbrave150 Trial
Co-led the pivotal IMbrave150 phase III trial demonstrating superior OS and PFS for atezolizumab plus bevacizumab over sorafenib in unresectable HCC, establishing a new standard of care.
First-Line Systemic Therapy
Shaped international guidelines for HCC systemic treatment through multiple landmark trials evaluating targeted agents and immune checkpoint inhibitors in advanced disease.
Representative Works 代表性著作
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine (2020)
IMbrave150 trial demonstrating OS benefit of atezo+bev over sorafenib; practice-changing for first-line advanced HCC.
Sorafenib in Advanced Hepatocellular Carcinoma (SHARP)
New England Journal of Medicine (2008)
Landmark SHARP trial establishing sorafenib as first systemic therapy to improve survival in advanced HCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 理查德·芬恩 的研究动态
Follow Richard S. Finn's research updates
留下邮箱，当我们发布与 Richard S. Finn（UCLA David Geffen School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment